Tromethamine

Identification

Name
Tromethamine
Accession Number
DB03754  (EXPT03072)
Type
Small Molecule
Groups
Approved
Description

An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)

Structure
Thumb
Synonyms
  • 1,1,1-tris(hydroxymethyl)methanamine
  • 2-Amino-2-(hydroxymethyl)-1,3-propanediol
  • aminotris(hydroxymethyl)methane
  • THAM
  • Tris
  • Tris(hydroxymethyl)aminomethane
  • Trometamol
External IDs
NSC-6365
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ThamInjection, solution3.6 g/100mLIntravenousHospira, Inc.2009-11-162018-02-08Us
Tham Solution 36mg/mlSolution36 mgIntravenousHospira, Inc.1972-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Sooryehan Hyo Fermented Sun BlockTromethamine (2.63 mL/100mL) + Amiloxate (1.6 mL/100mL) + Bemotrizinol (1 mL/100mL) + Diethylamino hydroxybenzoyl hexyl benzoate (1 mL/100mL) + Ensulizole (3.9 mL/100mL) + Octinoxate (7 mL/100mL) + Titanium dioxide (2.52 mL/100mL)CreamTopicalLg Household & Health Care Ltd.2011-09-27Not applicableUs
Categories
UNII
023C2WHX2V
CAS number
77-86-1
Weight
Average: 121.135
Monoisotopic: 121.073893223
Chemical Formula
C4H11NO3
InChI Key
LENZDBCJOHFCAS-UHFFFAOYSA-N
InChI
InChI=1S/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2
IUPAC Name
2-amino-2-(hydroxymethyl)propane-1,3-diol
SMILES
NC(CO)(CO)CO

Pharmacology

Indication

For the prevention and correction of metabolic acidosis.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAutolysinNot AvailableStreptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
UCytochrome c4Not AvailablePseudomonas stutzeri
USoluble calcium-activated nucleotidase 1Not AvailableHuman
ULipoprotein NlpINot AvailableEscherichia coli (strain K12)
UDNA protection during starvation proteinNot AvailableAgrobacterium tumefaciens (strain C58 / ATCC 33970)
UPutative glucose-6-phosphate 1-epimeraseNot AvailableHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UEndonuclease 8-like 1Not AvailableHuman
UCholera enterotoxin subunit BNot AvailableVibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)
US-adenosylmethionine decarboxylase proenzymeNot AvailableHuman
UBiotin synthaseNot AvailableEscherichia coli (strain K12)
UVascular endothelial growth factor ANot AvailableHuman
U6-phosphogluconolactonaseNot AvailableThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
UDecorinNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe bioavailability of 16-Bromoepiandrosterone can be decreased when combined with Tromethamine.Investigational
19-norandrostenedioneThe bioavailability of 19-norandrostenedione can be decreased when combined with Tromethamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamineTromethamine may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineTromethamine may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3,4-MethylenedioxyamphetamineTromethamine may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineTromethamine may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
5-androstenedioneThe bioavailability of 5-androstenedione can be decreased when combined with Tromethamine.Experimental, Illicit
AcepromazineTromethamine can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineTromethamine can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Tromethamine.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Tromethamine.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Tromethamine.Approved
AlimemazineTromethamine can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolTromethamine can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Tromethamine.Approved
AmphetamineTromethamine may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AndrostenedioneThe bioavailability of Androstenedione can be decreased when combined with Tromethamine.Experimental, Illicit
AnecortaveThe bioavailability of Anecortave can be decreased when combined with Tromethamine.Investigational
anecortave acetateThe bioavailability of anecortave acetate can be decreased when combined with Tromethamine.Investigational
AtamestaneThe bioavailability of Atamestane can be decreased when combined with Tromethamine.Investigational
AtazanavirTromethamine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Tromethamine.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Tromethamine.Approved, Investigational
BenzphetamineTromethamine may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Tromethamine.Approved, Vet Approved
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Tromethamine.Approved
Bismuth SubcitrateThe therapeutic efficacy of Bismuth Subcitrate can be decreased when used in combination with Tromethamine.Approved, Investigational
BL-1020Tromethamine can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Tromethamine.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Tromethamine.Approved
CaptoprilTromethamine can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Tromethamine.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Tromethamine.Approved, Vet Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Tromethamine.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Tromethamine.Approved, Withdrawn
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Tromethamine.Approved, Investigational, Vet Approved
ChlorphentermineTromethamine may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineTromethamine can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineTromethamine can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineTromethamine can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Tromethamine.Approved, Investigational
CinoxacinTromethamine can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinTromethamine can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Tromethamine.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Tromethamine.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Tromethamine.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Tromethamine.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Tromethamine.Approved, Investigational, Vet Approved
Cortexolone 17α-propionateThe bioavailability of Cortexolone 17α-propionate can be decreased when combined with Tromethamine.Investigational
CorticosteroneThe bioavailability of Corticosterone can be decreased when combined with Tromethamine.Experimental
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Tromethamine.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Tromethamine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Tromethamine.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Tromethamine.Approved, Investigational
DasatinibTromethamine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Tromethamine.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Tromethamine.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Tromethamine.Approved
DemeclocyclineTromethamine can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Tromethamine.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Tromethamine.Approved
Desoxycorticosterone acetateThe bioavailability of Desoxycorticosterone acetate can be decreased when combined with Tromethamine.Approved
Desoxycorticosterone PivalateThe bioavailability of Desoxycorticosterone Pivalate can be decreased when combined with Tromethamine.Experimental, Vet Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Tromethamine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Tromethamine.Vet Approved
DexmethylphenidateTromethamine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DextroamphetamineTromethamine may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DiethylpropionTromethamine may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Tromethamine.Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Tromethamine.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Tromethamine.Approved
Dipotassium phosphateTromethamine can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DoxycyclineTromethamine can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Tromethamine.Approved
EnoxacinTromethamine can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EquileninThe bioavailability of Equilenin can be decreased when combined with Tromethamine.Experimental
EquilinThe bioavailability of Equilin can be decreased when combined with Tromethamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Tromethamine.Approved, Investigational
EstroneThe bioavailability of Estrone can be decreased when combined with Tromethamine.Approved
Estrone sulfateThe bioavailability of Estrone sulfate can be decreased when combined with Tromethamine.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Tromethamine.Approved
Ferric CarboxymaltoseTromethamine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateTromethamine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Tromethamine.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Tromethamine.Approved, Withdrawn
FleroxacinTromethamine can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluasteroneThe bioavailability of Fluasterone can be decreased when combined with Tromethamine.Investigational
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Tromethamine.Approved, Investigational
FlumequineTromethamine can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Tromethamine.Approved, Vet Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Tromethamine.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Tromethamine.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Tromethamine.Approved, Investigational
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Tromethamine.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Tromethamine.Approved, Investigational
FluphenazineTromethamine can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Tromethamine.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Tromethamine.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Tromethamine.Approved
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Tromethamine.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Tromethamine.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Tromethamine.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Tromethamine.Approved
FormestaneThe bioavailability of Formestane can be decreased when combined with Tromethamine.Approved, Investigational, Withdrawn
FosinoprilTromethamine can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Tromethamine.Approved, Investigational
GarenoxacinTromethamine can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinTromethamine can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Tromethamine.Approved, Investigational
GemifloxacinTromethamine can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineTromethamine may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
GrepafloxacinTromethamine can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Tromethamine.Approved, Investigational, Withdrawn
HE3286The bioavailability of HE3286 can be decreased when combined with Tromethamine.Investigational
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Tromethamine.Approved, Vet Approved
HydroxyamphetamineTromethamine may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineThe serum concentration of Hyoscyamine can be decreased when it is combined with Tromethamine.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Tromethamine.Approved, Investigational
Iofetamine I-123Tromethamine may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronTromethamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranTromethamine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateTromethamine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsoniazidTromethamine can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
IstaroximeThe bioavailability of Istaroxime can be decreased when combined with Tromethamine.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Tromethamine.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Tromethamine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Tromethamine.Approved
LevofloxacinTromethamine can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LisdexamfetamineTromethamine may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LomefloxacinTromethamine can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Tromethamine.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Tromethamine.Approved, Investigational
ME-609The bioavailability of ME-609 can be decreased when combined with Tromethamine.Investigational
MecamylamineThe serum concentration of Mecamylamine can be increased when it is combined with Tromethamine.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Tromethamine.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Tromethamine.Vet Approved
MemantineThe serum concentration of Memantine can be increased when it is combined with Tromethamine.Approved, Investigational
MephedroneTromethamine may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineTromethamine may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Tromethamine.Approved
MesoridazineTromethamine can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethamphetamineTromethamine may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Tromethamine.Approved, Vet Approved
MethotrimeprazineTromethamine can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineTromethamine may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
Methylene blueTromethamine can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateTromethamine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Tromethamine.Approved, Vet Approved
MevastatinThe serum concentration of Mevastatin can be decreased when it is combined with Tromethamine.Experimental
MidomafetamineTromethamine may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
MinocyclineTromethamine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MisoprostolThe risk or severity of adverse effects can be increased when Tromethamine is combined with Misoprostol.Approved
MMDATromethamine may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MometasoneThe bioavailability of Mometasone can be decreased when combined with Tromethamine.Approved, Vet Approved
MoricizineTromethamine can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
MoxifloxacinTromethamine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Mycophenolic acidTromethamine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Nalidixic AcidTromethamine can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NCX 1022The bioavailability of NCX 1022 can be decreased when combined with Tromethamine.Investigational
NemonoxacinTromethamine can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Tromethamine.Approved, Investigational
NorfloxacinTromethamine can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OfloxacinTromethamine can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Oleoyl-estroneThe bioavailability of Oleoyl-estrone can be decreased when combined with Tromethamine.Investigational
Oxolinic acidTromethamine can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineTromethamine can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Tromethamine.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Tromethamine.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Tromethamine.Approved
PazufloxacinTromethamine can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinTromethamine can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenicillamineThe serum concentration of Penicillamine can be decreased when it is combined with Tromethamine.Approved
PerazineTromethamine can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerphenazineTromethamine can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PhentermineTromethamine may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Pipemidic acidTromethamine can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidTromethamine can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Tromethamine.Approved
PrasteroneThe bioavailability of Prasterone can be decreased when combined with Tromethamine.Approved, Investigational, Nutraceutical
Prasterone sulfateThe bioavailability of Prasterone sulfate can be decreased when combined with Tromethamine.Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Tromethamine.Approved
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Tromethamine.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Tromethamine.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Tromethamine.Approved, Vet Approved
PregnenoloneThe bioavailability of Pregnenolone can be decreased when combined with Tromethamine.Approved, Experimental, Investigational
ProchlorperazineTromethamine can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineTromethamine can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineTromethamine can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineTromethamine can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineTromethamine can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
PrulifloxacinTromethamine can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PseudoephedrineTromethamine may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
QuinidineTromethamine may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
QuinineThe serum concentration of Quinine can be decreased when it is combined with Tromethamine.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Tromethamine.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Tromethamine.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Tromethamine.Approved, Investigational
RitobegronTromethamine may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RosoxacinTromethamine can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Tromethamine.Approved
RufloxacinTromethamine can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Tromethamine.Approved
SitafloxacinTromethamine can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateTromethamine can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateTromethamine can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolThe serum concentration of Sotalol can be decreased when it is combined with Tromethamine.Approved
SparfloxacinTromethamine can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SulpirideThe serum concentration of Sulpiride can be decreased when it is combined with Tromethamine.Approved, Investigational
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Tromethamine.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Tromethamine.Approved
TemafloxacinTromethamine can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TetracyclineTromethamine can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
ThiazinamTromethamine can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineTromethamine can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineTromethamine can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThioridazineTromethamine can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Tromethamine.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Tromethamine.Approved, Withdrawn
TolevamerThe risk or severity of adverse effects can be increased when Tromethamine is combined with Tolevamer.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Tromethamine.Approved, Vet Approved
TriethylenetetramineTromethamine can cause a decrease in the absorption of Triethylenetetramine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TrifluoperazineTromethamine can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineTromethamine can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrovafloxacinTromethamine can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Tromethamine.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Tromethamine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Jean Bourguignon, Marcel-Xavier Sion, Michel Moreau, "Preparation of tris(hydroxymethyl)aminomethane." U.S. Patent US4233245, issued August, 1959.

US4233245
General References
Not Available
External Links
KEGG Drug
D00396
KEGG Compound
C07182
PubChem Compound
6503
PubChem Substance
46506027
ChemSpider
6257
ChEBI
9754
ChEMBL
CHEMBL1200391
HET
TRS
Wikipedia
Tris
ATC Codes
B05XX02 — TrometamolB05BB03 — Trometamol
AHFS Codes
  • 40:08.00 — Alkalinizing Agents
FDA label
Download (88.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingPreventionCystic Fibrosis (CF) / Healthy Volunteers1
2, 3RecruitingTreatmentPain, Acute1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical
Injection, solutionIntravenous3.6 g/100mL
SolutionIntravenous36 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility695.0 mg/mLALOGPS
logP-2.1ALOGPS
logP-2.7ChemAxon
logS0.76ALOGPS
pKa (Strongest Acidic)14.16ChemAxon
pKa (Strongest Basic)8.95ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area86.71 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity28.36 m3·mol-1ChemAxon
Polarizability12.02 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.52
Blood Brain Barrier-0.6989
Caco-2 permeable-0.6613
P-glycoprotein substrateNon-substrate0.6664
P-glycoprotein inhibitor INon-inhibitor0.9749
P-glycoprotein inhibitor IINon-inhibitor0.9671
Renal organic cation transporterNon-inhibitor0.9239
CYP450 2C9 substrateNon-substrate0.8432
CYP450 2D6 substrateNon-substrate0.8337
CYP450 3A4 substrateNon-substrate0.8096
CYP450 1A2 substrateNon-inhibitor0.8179
CYP450 2C9 inhibitorNon-inhibitor0.9095
CYP450 2D6 inhibitorNon-inhibitor0.9027
CYP450 2C19 inhibitorNon-inhibitor0.895
CYP450 3A4 inhibitorNon-inhibitor0.9568
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9686
Ames testNon AMES toxic0.9257
CarcinogenicityNon-carcinogens0.7844
BiodegradationReady biodegradable0.582
Rat acute toxicity1.5129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9739
hERG inhibition (predictor II)Non-inhibitor0.9664
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-53da6b0f35ab1e8e8a57
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0pi0-7900000000-244b89c0e2e656701b1d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-a468801012da982d3bac
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-eb66f99d48d2027e0fb2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-9000000000-2983a91b4350760fab44

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
1,2-aminoalcohols
Alternative Parents
Primary alcohols / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
1,2-aminoalcohol / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine / Primary alcohol / Organooxygen compound / Primary aliphatic amine / Alcohol / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
primary amino compound, triol (CHEBI:9754) / a small molecule (TRIS)

Targets

Kind
Protein
Organism
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4)
Pharmacological action
Unknown
General Function
N-acetylmuramoyl-l-alanine amidase activity
Specific Function
Autolysins are involved in some important biological processes such as cell separation, cell-wall turnover, competence for genetic transformation, formation of the flagella and sporulation. Autolys...
Gene Name
lytA
Uniprot ID
P06653
Uniprot Name
Autolysin
Molecular Weight
36544.235 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Pseudomonas stutzeri
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Diheme, high potential cytochrome c believed to be an intermediate electron donor to terminal oxidation systems.
Gene Name
cc4
Uniprot ID
Q52369
Uniprot Name
Cytochrome c4
Molecular Weight
21741.505 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Uridine-diphosphatase activity
Specific Function
Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards...
Gene Name
CANT1
Uniprot ID
Q8WVQ1
Uniprot Name
Soluble calcium-activated nucleotidase 1
Molecular Weight
44839.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
May be involved in cell division. May play a role in bacterial septation or regulation of cell wall degradation during cell division. Negatively controls the production of extracellular DNA (eDNA).
Gene Name
nlpI
Uniprot ID
P0AFB1
Uniprot Name
Lipoprotein NlpI
Molecular Weight
33620.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Agrobacterium tumefaciens (strain C58 / ATCC 33970)
Pharmacological action
Unknown
General Function
Oxidoreductase activity, oxidizing metal ions
Specific Function
Protects DNA from oxidative damage by sequestering intracellular Fe(2+) ion and storing it in the form of Fe(3+) oxyhydroxide mineral, which can be released after reduction. It efficiently inhibits...
Gene Name
dps
Uniprot ID
Q8UCK6
Uniprot Name
DNA protection during starvation protein
Molecular Weight
17822.915 Da
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Carbohydrate binding
Gene Name
Not Available
Uniprot ID
P44160
Uniprot Name
Putative glucose-6-phosphate 1-epimerase
Molecular Weight
Not Available
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
NEIL1
Uniprot ID
Q96FI4
Uniprot Name
Endonuclease 8-like 1
Molecular Weight
43683.625 Da
Kind
Protein
Organism
Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961)
Pharmacological action
Unknown
General Function
Host cell surface binding
Specific Function
The B subunit pentameric ring directs the A subunit to its target by binding to the GM1 gangliosides present on the surface of the intestinal epithelial cells. It can bind five GM1 gangliosides. It...
Gene Name
ctxB
Uniprot ID
P01556
Uniprot Name
Cholera enterotoxin subunit B
Molecular Weight
13957.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Putrescine binding
Specific Function
Essential for biosynthesis of the polyamines spermidine and spermine. Promotes maintenance and self-renewal of embryonic stem cells, by maintaining spermine levels (By similarity).
Gene Name
AMD1
Uniprot ID
P17707
Uniprot Name
S-adenosylmethionine decarboxylase proenzyme
Molecular Weight
38339.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Iron ion binding
Specific Function
Catalyzes the conversion of dethiobiotin (DTB) to biotin by the insertion of a sulfur atom into dethiobiotin via a radical-based mechanism.
Gene Name
bioB
Uniprot ID
P12996
Uniprot Name
Biotin synthase
Molecular Weight
38647.785 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)
Pharmacological action
Unknown
General Function
6-phosphogluconolactonase activity
Specific Function
Hydrolysis of 6-phosphogluconolactone to 6-phosphogluconate.
Gene Name
pgl
Uniprot ID
Q9X0N8
Uniprot Name
6-phosphogluconolactonase
Molecular Weight
25324.955 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Poly(a) rna binding
Specific Function
May affect the rate of fibrils formation.
Gene Name
DCN
Uniprot ID
P07585
Uniprot Name
Decorin
Molecular Weight
39746.43 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on June 16, 2018 22:13